882:
Role of anti-inflammatory cytokine IL-35 in the effects of sublingual immunotherapy
Monday, March 5, 2018
South Hall A2 (Convention Center)
Hideaki Kouzaki, MD, Atsushi Yuta, MD, Masahiko Arikata, Takeshi Shimizu
RATIONALE:

The immunologic tolerant state following allergen immunotherapy is associated with the induction of distinct phenotypes of regulatory T-cells or B-cells. IL-35 was recently identified as an anti-inflammatory cytokine. However, IL-35 bioactivity is not fully understood in human. We investigated the role of IL-35 production in the effects of sublingual immunotherapy (SIT).

METHODS:

The bioactivity of human recombinant IL-35 was examined using PBMC from patients with Japanese cedar pollinosis (JCP). A prospective study was undertaken to evaluate the effects of SIT on IL-35 production from T cells and B cells.

RESULTS:

Human recombinant IL-35 suppressed Japanese cedar pollen-induced production of IL-5, IFN-g, and IL-17, but not IL-10 from PBMC of JCP patients. Human recombinant IL-35 directly suppressed IL-5 and IL-13 production from memory CD4+ T-cells and from cocultured DCs/CD4+ T cells. The percentage of IL-35 positive CD4+ T-cells and IL-35 positive B-cells increased after one year treatment of SLIT. IL-35 protein from PBMC of JCP patients increased after SIT. Symptom medication score and serum IL-35 concentration of JCP patients in the peak season showed opposite correlation after SLIT.

CONCLUSIONS:

IL-35 plays an important role in the suppression of Th2 type inflammation, and increased production of IL-35 from T cells and B cells after SLIT may influence effector cells in allergic rhinitis. Augmentation of constitutive IL-35 production from immune system is a potential therapeutic approach for allergic disorders.